Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More


Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy

Study identifier: NCT00892736
Full study details on

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)


  • Documented BRCA1/2 mutation AND a BRCA-related malignancy (e.g., primarily
    breast or ovarian cancer, but may include prostate or pancreatic cancer) or triple-
    negative breast cancer. Progressive disease after standard therapy OR no acceptable standard treatment options available.
  • Platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer
  • Patients with platinum-sensitive disease must have known BRCA mutations
  • Basal-like breast cancer, defined as estrogen and progesterone receptor-negative, HER2-negative, and/or expression profile of EGFR and cytokeratins 5/6 consistent with basal phenotype
    "Triple-negative" phenotype (i.e., negative hormone and HER2 receptors) allowed

Type of study:

Phase I


  • Patients receive oral ABT-888 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or toxicity.

Study sites:

City of Hope
Contact: Robert J. Morgan 626-256-4673

Los Angeles
University of Southern California
Contact: Agustin A. Garcia 323-865-0832

UC Davis Comprehensive Cancer Center
Contact: David R. Gandara 916-734-3772

South Pasadena
City of Hope - South Pasadena
Contact: Stephen C. Koehler 626-396-2900

New Jersey
New Brunswick
Cancer Institute of New Jersey
Contact: Antoinette R. Tan 732-235-6777

Penn State Milton S Hershey Medical CenterPennsylvania
Contact: Chandra P. Belani 717-531-1078

UPMC Cancer Center
Contact: Clinical Trials Office - UPMC Cancer Centers     412-647-8073  


Page updated 06/09/13

FORCE:Facing Our Risk of Cancer Empowered